During the Multiple Myeloma Patient Symposium, Ken Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses treatment options for multiple myeloma. According to Dr Anderson, triplet therapy for relapsed multiple myeloma can achieve deep, durable responses. BCMA CAR T and bispecific T-cell engager therapies may also be beneficial in patients with multiple myeloma refractory to other treatments.